EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-World Survival Outcomes Following Chemoradiotherapy with or Without Durvalumab in PD-L1-Defined Subgroups of Stage III Unresectable NSCLC

Janne Selke iD, Yvonne Dzierma, Katrin Manda iD, Guido Hildebrandt iD, Bernd Frerker iD, Paul Kalata, Christin Ackermann iD, Felix Bock iD

Current Oncology · 10.06.2026 · 33 (6) · 351

DOI: 10.3390/curroncol33060351 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, online erschienen am 10.06.2026. Verfasst von Janne Selke und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiotherapy and Radiation Oncology, Rostock University Medical Centre, 18059 Rostock, Germany. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Carcinoma, Non-Small-Cell Lung, Chemoradiotherapy, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Durvalumab consolidation after definitive chemoradiotherapy (CRT) is the standard of care for unresectable stage III non-small cell lung cancer (NSCLC) but real-world data comparing PD-L1-defined subgroups are limited. This retrospective single-centre study analyzed overall survival (OS) and progression-free survival (PFS) in 142 patients with inoperable stage III NSCLC with definitive CRT between 2015 and 2022. All tumours were assessed for PD-L1 expression, including retrospective testing, where required. Patients were assigned into three cohorts: PD-L1-positive with (PD-L1+mD; n = 57) and without (PD-L1+oD; n = 44) durvalumab maintenance and PD-L1-negative without durvalumab (PD-L1−oD; n = 41). Mean follow-up was 44.0 months. Median OS was 27.3, 15.1 and 23.4 months for PD-L1+mD, PD-L1+oD, and PD-L1−oD, respectively. Median PFS was 18.4, 10.5 and 13.4 months for PD-L1+mD, PD-L1+oD, and PD-L1−oD, respectively. OS and PFS were significantly improved with durvalumab in PD-L1-positive patients (p = 0.043 and p = 0.027). PD-L1-negative patients showed no significant OS or PFS differences versus PD-L1+oD. Immunotherapy-related pneumonitis ≥grade 1 was documented in 15.7% patients. In real-world practice, durvalumab improves OS and PFS in PD-L1-positive unresectable stage III NSCLC and its omission appears particularly unfavourable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalCarcinoma, Non-Small-Cell LungChemoradiotherapyLung NeoplasmsB7-H1 AntigenAntineoplastic Agents, ImmunologicalHumansFemaleRetrospective StudiesMaleNeoplasm StagingAgedMiddle AgedAdultAged, 80 and over

Stichwörter der Autor:innen

PD-L1chemoradiotherapydurvalumablocally advanced non-small cell lung cancerreal-world evidencestage III

Substanzen

durvalumabAntibodies, MonoclonalB7-H1 AntigenAntineoplastic Agents, ImmunologicalCD274 protein, human

Autor:innen und Institutionen

  • Department of Radiotherapy and Radiation Oncology, Rostock University Medical Centre, 18059 Rostock, Germany.
  • Institute of Hematopathology Hamburg HpH, 22547 Hamburg, Germany.

ORCID-Profile: Janne Selke, Katrin Manda, Guido Hildebrandt, Bernd Frerker, Christin Ackermann, Felix Bock

Zitieren

APA

Selke, J., Dzierma, Y., Manda, K., Hildebrandt, G., Frerker, B., Kalata, P., Ackermann, C., & Bock, F. (2026). Real-World Survival Outcomes Following Chemoradiotherapy with or Without Durvalumab in PD-L1-Defined Subgroups of Stage III Unresectable NSCLC. Current Oncology, 33(6), 351. https://doi.org/10.3390/curroncol33060351

Vancouver

Selke J, Dzierma Y, Manda K, Hildebrandt G, Frerker B, Kalata P, et al. Real-World Survival Outcomes Following Chemoradiotherapy with or Without Durvalumab in PD-L1-Defined Subgroups of Stage III Unresectable NSCLC. Current Oncology. 2026;33(6):351. doi:10.3390/curroncol33060351

BibTeX
@article{Selke2026,
  author = {Selke, Janne and Dzierma, Yvonne and Manda, Katrin and Hildebrandt, Guido and Frerker, Bernd and Kalata, Paul and Ackermann, Christin and Bock, Felix},
  title = {Real-World Survival Outcomes Following Chemoradiotherapy with or Without Durvalumab in PD-L1-Defined Subgroups of Stage III Unresectable NSCLC},
  journal = {Current Oncology},
  year = {2026},
  volume = {33},
  number = {6},
  pages = {351},
  doi = {10.3390/curroncol33060351}
}
Kostenlos starten →